Eye Retina Anatomy Diagram

Research confirms the benefit of supplementation for slowing vision loss from AMD

After 10 years, the AREDS2 formula shows increased efficacy compared to the original formula, which is the beta-carotene elimination advantage.

Age-related macular degeneration (AMD) is an eye disease that can blur central vision. It is very common in the United States, especially among older adults and white Americans, making it the leading cause of vision loss in the United States. In addition to regular physical activity, quitting smoking, and maintaining healthy blood pressure and cholesterol levels, supplementation can help reduce the risk for AMD or slow offer it.

Age-related eye disease studies (AREDS and AREDS2) have demonstrated that nutritional supplements can slow the progression of age-related macular degeneration (AMD), the most common cause of blindness in older Americans. In a new report, scientists analyzed 10 years of AREDS2 data. They show that the AREDS2 formula, which has replaced the antioxidants lutein and zeaxanthin for beta-carotene, not only reduces the risk of lung cancer due to beta-carotene, but is also more effective in reducing the risk of developing AMD, compared to the original formula. A report on the study funded by the National Institutes of Health was published in the journal Gamma Ophthalmology On June 2, 2022.

Age-related macular degeneration (AMD) It is an eye disease that can blur your central vision. It occurs when aging damages the macula – the part of the eye that controls sharp and direct vision. The macula is part of the retina (the light-sensitive tissue at the back of the eye). AMD is a common condition – it is a major cause of vision loss in the elderly.

“Because beta-carotene increased lung cancer risk for current smokers in two studies supported by the National Institutes of Health, our goal with AREDS2 was to create an equally effective supplement formulation that anyone can use, whether smoker or not,” said Emily Chiu. MD, director of the division of epidemiology and clinical application at the National Eye Institute (NEI), and lead author of the study report. “These 10 years of data confirm that the new formula is not only safer, but is actually better at slowing the progression of AMD.”

AMD is a degenerative disease that affects the retina, the light-sensitive tissue at the back of the eye. The gradual death of retinal cells in the macula, the part of the retina that provides clear central vision, eventually leads to blindness. Treatment can slow or reverse vision loss; However, there is no cure for AMD.

The original AREDS study, begun in 1996, showed that a supplement combination (500 mg vitamin C, 400 IU vitamin E, 2 mg copper, 80 mg zinc, and 15 mg beta-carotene) could slow significantly reduces the progression of AMD from a moderate to late disease. However, two simultaneous studies also revealed that people who smoke and take beta-carotene have a higher risk of developing lung cancer than expected.

Emily Chiu doing an eye exam

Dr. Emily Chiu of the National Eye Institute performs an eye exam. credit: NEI

In AREDS2, launched in 2006, Chew and colleagues compared the combination of beta-carotene to a preparation containing 10 mg lutein and 2 mg zeaxanthin instead. Like beta-carotene, lutein and zeaxanthin are antioxidants that have activity in the retina of the eye. The beta-carotene-containing formulation was given only to participants who had never smoked or who had quit.

AMD develops slowly in some people and rapidly in others. If you have early AMD, you may not notice vision loss for a long time. This is why it is essential to have frequent eye exams to determine if you have AMD.

At the end of the five-year AREDS2 study period, the researchers concluded that lutein and zeaxanthin do not increase the risk of lung cancer, and that the new composition can reduce the risk of developing AMD by about 26%. After completing the five-year study period, all study participants were shown a final AREDS2 profile that included lutein and zeaxanthin instead of beta-carotene.

In this new report, researchers followed 3,883 out of 4,203 AREDS2 participants for an additional five years from the end of the AREDS2 study in 2011, and collected information about whether AMD had progressed to late disease, and whether they had been diagnosed with the disease. Lung Cancer. Although all participants switched to the formula containing lutein and zeaxanthin after the end of the study period, the follow-up study continued to show that beta-carotene increased the risk of lung cancer for people who had previously smoked nearly twice as much. There was no increased risk of lung cancer in those receiving lutein/zeaxanthin. Additionally, after 10 years, the group originally assigned to receive lutein/zeaxanthin had a 20% additional risk of progressing to late-onset AMD compared to the group originally assigned to receive beta-carotene.

“These results confirmed that switching our formula from beta-carotene to lutein and zeaxanthin was the right choice,” Chiu said.

Reference: “Long-term results of adding lutein/zeaxanthin and beta-3 fatty acids to AREDS supplementation on the development of age-related macular degeneration: AREDS2 Report No. 28” by Emily Y Chiu, MD; Traci E. Clemons, PhD; Elvira Agron, Massachusetts; Amitha Doumalbali, MD, PhD; Tiarnán DL. Keenan, BM, BCh, PhD; Susan Vitale, Ph.D.; Claire Webber, MA; Douglas C. Smith, B.A. and William Christine, C. AREDS2 Research Group, 2 Jun 2022, Available here. Gamma Ophthalmology.
DOI: 10.1001/jamaophthalmol.2022.1640

The study was funded by the NEI Intramural Program (EY000546) and through contracts (AREDS2 contract HHS-N-260-2005-00007-C; ADB contract NO1-EY-5-0007; AREDS contract NOI-EY-0-2127 , Contract HHS-N-263-2013-00005-C). AREDS2 contracts were supported by the NIH Office of Nutritional Supplements, the National Center for Complementary and Integrative Health, the National Institute on Aging, the National Heart, Lung, and Blood Institute, and the National Institute of Neurological Disorders and Stroke. The study was conducted at the National Institutes of Health Medical Center.

2022-06-06 11:27:09

Leave a Comment

Your email address will not be published. Required fields are marked *